Navigation Links
Schering-Plough CEO to Buy $2 Million in Common Shares
Date:1/18/2008

KENILWORTH, N.J., Jan. 18 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced this morning that Chairman and CEO Fred Hassan intends to make an open market purchase of $2 million of Schering-Plough Common Shares with personal funds.

"As was the case in November 2003 when I purchased $4.68 million in Schering-Plough Common Shares at an average price of $15.42 (2003 press release below), this investment in Schering-Plough reflects my long-term confidence in the company, its products (including ZETIA and VYTORIN), and our late-stage pipeline," said Hassan. "The media interpretations of the top-line ENHANCE trial results, and the resulting stock price reaction, have been deeply troubling. I firmly believe in VYTORIN and ZETIA. Further, I believe this company is now a strong and diverse global competitor, with sound long- term fundamentals, that is capable of driving long-term growth. Our mission is 'To earn trust, every day,' and this personal stock purchase reflects my faith that, together, our 50,000 dedicated Schering-Plough employees can accomplish that mission."

Hassan had wanted to purchase the stock yesterday, when the stock closed at $21.62. However, it was determined that, under the federal securities laws, it would be better to defer the purchase until earnings for the fourth quarter and the full year 2007 are announced, scheduled for Feb. 12, 2008, and the full results of the ENHANCE trial are discussed in a scientific forum, anticipated for the American College of Cardiology meeting in late March. Hassan committed that the purchase will then be completed, whatever the stock price at that time. "I had already made a significant personal investment in Schering-Plough in 2003, and I believe that adding another $2 million to this personal investment is the right thing to do."

BELOW: 2003 PRESS RELEASE ON CEO STOCK PURCHASE

SCHERING-PLOUGH CEO BUYS $4.68 MILLION OF COMPANY COMMON STOCK

KENILWORTH, N.J., Nov. 28, 2003 -- Schering-Plough Corporation (NYSE: SGP) today announced that Fred Hassan, chairman and chief executive officer, purchased $4.68 million worth of Schering-Plough common stock, representing 303,500 shares.

Hassan had previously expressed his intention to acquire shares of the company, as reported in Investor Frequently Asked Questions (FAQs) filed with an 8-K/A with the U.S. Securities and Exchange Commission on Aug. 13, 2003.

"This investment in Schering-Plough reflects my long-term confidence in the company," said Hassan. He noted that within a few months of joining Pharmacia & Upjohn in 1997 he had purchased an amount of that company's common shares. Hassan joined Schering-Plough in April 2003.

"As we said at last week's meeting with analysts and investors, there are still significant challenges facing Schering-Plough, but I firmly believe this company can be turned around and become a highly competitive global organization that should be capable of producing long-term growth," said Hassan.

DISCLOSURE NOTICE: This press release may contain "forward-looking statements" about the company's business or prospects. Many factors could cause actual results to differ from the forward-looking statements. The company does not assume any obligation to update any forward-looking statement. For further details and a discussion of risks and uncertainties that may affect forward-looking statements, see the company's current and future Securities and Exchange Commission (SEC) filings, including the third quarter 2003 10-Q.

Schering-Plough is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide.

# # #

ABOUT SCHERING-PLOUGH

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
3. Schering-Plough Reports Financial Results for Third Quarter of 2007
4. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
5. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
6. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
7. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
10. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
11. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
Breaking Medicine Technology: